Sofía De la Villa , Miguel Cuervo , Pilar Domingo-Calap , Patricia Muñoz
{"title":"Successful phage therapy in a patient with prosthetic joint infection","authors":"Sofía De la Villa , Miguel Cuervo , Pilar Domingo-Calap , Patricia Muñoz","doi":"10.1016/j.eimce.2025.05.011","DOIUrl":"10.1016/j.eimce.2025.05.011","url":null,"abstract":"","PeriodicalId":72916,"journal":{"name":"Enfermedades infecciosas y microbiologia clinica (English ed.)","volume":"43 8","pages":"Pages 535-536"},"PeriodicalIF":0.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145190048","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Grace Oscullo , Jose Daniel Gómez-Olivas , Miguel Angel Martinez-Garcia
{"title":"Bronchiectasis: Is there life beyond Pseudomonas aeruginosa?","authors":"Grace Oscullo , Jose Daniel Gómez-Olivas , Miguel Angel Martinez-Garcia","doi":"10.1016/j.eimce.2025.06.008","DOIUrl":"10.1016/j.eimce.2025.06.008","url":null,"abstract":"","PeriodicalId":72916,"journal":{"name":"Enfermedades infecciosas y microbiologia clinica (English ed.)","volume":"43 8","pages":"Pages 461-463"},"PeriodicalIF":0.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145190131","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
María Calle Romero, Patricia de la Montaña Díaz, Montserrat Rodríguez Gómez, Fernando Martínez Sagasti
{"title":"Uncommon presentation of meningococcal cellulitis during SARS-CoV-2 infection.","authors":"María Calle Romero, Patricia de la Montaña Díaz, Montserrat Rodríguez Gómez, Fernando Martínez Sagasti","doi":"10.1016/j.eimce.2025.09.002","DOIUrl":"https://doi.org/10.1016/j.eimce.2025.09.002","url":null,"abstract":"","PeriodicalId":72916,"journal":{"name":"Enfermedades infecciosas y microbiologia clinica (English ed.)","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145093053","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Sofía Narváez , Natalia Arnalda , Marisa López , Andrea Vergara , Vanessa Guilera , Iván Chivite , David García-Hernández , Ana González-Cordón , Josep Riera-Monroig , Irene Fuertes , Josep Mallolas , José Luis Blanco , Jordi Bosch
{"title":"Detection of Neisseria gonorrhoeae and Chlamydia trachomatis by PCR in a sample pool (urine, rectum and pharynx) in asymptomatic patients at risk of sexually transmitted infections","authors":"Sofía Narváez , Natalia Arnalda , Marisa López , Andrea Vergara , Vanessa Guilera , Iván Chivite , David García-Hernández , Ana González-Cordón , Josep Riera-Monroig , Irene Fuertes , Josep Mallolas , José Luis Blanco , Jordi Bosch","doi":"10.1016/j.eimce.2024.11.009","DOIUrl":"10.1016/j.eimce.2024.11.009","url":null,"abstract":"<div><h3>Introduction</h3><div>Detection of <em>Neisseria gonorrhoeae</em> (NG) and <em>Chlamydia trachomatis</em> (CT) is periodically indicated in asymptomatic patients with risky sexual practices. The objective of this study was to assess the efficacy of employing a rapid polymerase chain reaction (PCR) test in a combined pool of three samples from the same patient and compare it with the standard PCR performed in the three different samples separately.</div></div><div><h3>Methods</h3><div>Samples were collected from asymptomatic patients at risk of sexually transmitted infections (STI). Urine samples, two pharyngeal swabs, and two rectal swabs were collected from each patient. Two PCR techniques were performed: standard PCR (Allplex CT/NG/MG/TV®, Seegene) in each of the three samples separately, and rapid PCR (Xpert CT/NG®, Cepheid) in a pool of three samples.</div></div><div><h3>Results</h3><div>A total of 429 pooled samples from 403 patients were included in the study, and 426 urine samples, 412 rectal swabs and 426 pharyngeal swabs were also processed. Concordances between pooled and individual PCRs for both CT and NG identification were 94.17%, with 77 (17.9%) positive samples. The concordance for CT was 98.60%, with 38 positive samples (8.88%), being 95.33% for NG, with 51 positive samples (11.88%).</div></div><div><h3>Conclusion</h3><div>The use of a pool of three samples (urine, rectum and pharynx) for the detection of NG and CT using rapid PCR can be a cost-effective alternative to performing conventional PCR in the three samples separately in asymptomatic patients at risk of developing STI.</div></div>","PeriodicalId":72916,"journal":{"name":"Enfermedades infecciosas y microbiologia clinica (English ed.)","volume":"43 7","pages":"Pages 374-377"},"PeriodicalIF":0.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144748928","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Verònica Torras-Vives , Cinta de Diego-Cabanes , Eva M. Satué-Gracia , Maria José Forcadell-Peris , Olga Ochoa-Gondar , Ángel Vila-Córcoles
{"title":"Incidence of pneumococcal and all-cause pneumonia in adults in Catalonia following the implementation of universal pneumococcal vaccination in children: 2015–2016 vs. 2017–2018","authors":"Verònica Torras-Vives , Cinta de Diego-Cabanes , Eva M. Satué-Gracia , Maria José Forcadell-Peris , Olga Ochoa-Gondar , Ángel Vila-Córcoles","doi":"10.1016/j.eimce.2025.03.005","DOIUrl":"10.1016/j.eimce.2025.03.005","url":null,"abstract":"<div><h3>Introduction</h3><div>To analyze the incidence of pneumonia in adults following public funding of the 13-valent pneumococcal conjugate vaccine (PCV13) for children in Catalonia.</div></div><div><h3>Methods</h3><div>Two cohorts were analyzed: 2,025,730 individuals aged ≥50 years in 2015–2016 (pre-funding) and 2,059,645 in 2017–2018 (post-funding). Hospitalizations for pneumococcal pneumonia (PP) and all-cause pneumonia (ACP) were identified through the CMBD database across 68 Catalonian hospitals. Incidence rate ratios (IRR) between periods were estimated.</div></div><div><h3>Results</h3><div>PP incidence increased from 83.6/100,000 (2015–2016) to 90.7/100,000 (2017–2018) (IRR: 1.09; 95%CI: 1.03–1.14), while ACP decreased slightly from 617.9/100,000 to 609.7/100,000 (IRR: 0.99; 95%CI: 0.97–1.00). ACP reductions were significant in individuals aged 65–79, those with chronic lung disease, and men. PP increased significantly in those aged<!--> <!-->><!--> <!-->80 years.</div></div><div><h3>Conclusion</h3><div>Adult hospitalized pneumonia incidence did not significantly decrease in the two years following PCV13 public funding for children.</div></div>","PeriodicalId":72916,"journal":{"name":"Enfermedades infecciosas y microbiologia clinica (English ed.)","volume":"43 7","pages":"Pages 444-447"},"PeriodicalIF":0.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143744419","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"A simplified extraction method reduces the processing time for proteomic identification of nontuberculous mycobacteria","authors":"Ramiro López-Medrano , Isabel Burgos-Asurmendi , Octavio Rivero-Lezcano","doi":"10.1016/j.eimce.2025.03.016","DOIUrl":"10.1016/j.eimce.2025.03.016","url":null,"abstract":"<div><h3>Introduction</h3><div>The identification of nontuberculous mycobacteria (NTM) by proteomic procedures has improved in the last few years. Strains from different geographical locations differ in their proteomic patterns, limiting the applicability of general databases for accurate identifications.</div></div><div><h3>Methods</h3><div>We have optimized an alternative extraction protocol to Myco-Ex, and MBT, the protocols recommended by Bruker Daltonics, the manufacturer of MALDI Biotyper, a Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry (MALDI-TOF MS) system. 120 clinical isolates, one environmental strain (<em>Mycobacterium canariasense</em>) and 7 quality controls were tested from the Spanish Society of Clinical Microbiology and Infectious Diseases (SEIMC). All strains were also sent to the Laboratory of Mycobacteria belonging to the National Spanish Reference Center (Instituto de Salud Carlos III), that uses several molecular methods for mycobacterial identification. The proteomic extraction method includes a single extraction/inactivation formic acid step. 30 NTM strains were analyzed to certify the biosafety of the procedure, testing their viability after this procedure.</div></div><div><h3>Results</h3><div>The score ranges of the isolates were 1.61–2.16 (mean 1, 84) for the 88 isolates of the slow growing mycobacteria group (SGM) and 1.66–2.33 (mean 2.06) for the 40 isolates of the rapid growing mycobacteria group (RGM). Isolates exposed to formic acid were incubated for 8 weeks and growth was observed in neither the clinical isolates nor the controls.</div></div><div><h3>Conclusions</h3><div>We have developed a simpler and faster procedure for the proteomic identification of nontuberculous mycobacteria (MALDI-TOF) retaining significant scores without compromising biosafety.</div></div>","PeriodicalId":72916,"journal":{"name":"Enfermedades infecciosas y microbiologia clinica (English ed.)","volume":"43 7","pages":"Pages 411-415"},"PeriodicalIF":0.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144227842","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Teresa Rodrigo , Joan P. Millet , Mario Bravo , Eva M. Tabernero , Joan A. Caylà , Tuberculosis Prevention and Control Programmes of the Autonomous Communities Working Group
{"title":"Evolution of tuberculosis in Spain: Will the objectives of the End TB Strategy be achieved in Western European countries?","authors":"Teresa Rodrigo , Joan P. Millet , Mario Bravo , Eva M. Tabernero , Joan A. Caylà , Tuberculosis Prevention and Control Programmes of the Autonomous Communities Working Group","doi":"10.1016/j.eimce.2025.02.017","DOIUrl":"10.1016/j.eimce.2025.02.017","url":null,"abstract":"<div><h3>Objectives</h3><div>End TB Strategy aims to reduce the incidence of tuberculosis between 2015 and 2025 milestone by 50%. We analyse whether the decreasing incidence objectives of this strategy can be achieved in Spain with the impact of COVID-19 pandemic and to review the incidence evolution in Western European countries (WEC).</div></div><div><h3>Study design</h3><div>Retrospective longitudinal ecological study with forecasting.</div></div><div><h3>Methodology</h3><div>An exponential curve was fitted to the Spanish and WEC data prior the pandemic period and projected with the model until 2025 using a 90% confidence interval to have better precision due to the sample size.</div></div><div><h3>Results</h3><div>The mean annual % change in incidence rates of TB in the three most affected WEC during 2018–2022 decreased by 6.5% in Spain, by 6.0% in Portugal, by 3.8% in Belgium and by 5.7% in France. The annual decrease in Spain in the first year of COVID-19 pandemic was 16.6%. Lower declines than in Spain were observed in most WEC. The probability of achieving the objective of reducing the incidence by 50% between 2015 and 2025 in Spain is, with a certainty of 90%, 0%, but with important differences by regions from 0% to 79%. These probabilities in Portugal, Belgium, France and Italy are also 0%.</div></div><div><h3>Conclusion</h3><div>With this epidemiological evolution, the main objective of the End TB Strategy for 2025 milestone (50% incidence decline) will not be achieved in Spain. The 80% decline will probably not be reached by 2030 unless surveillance and control are improved, and TB Programmes are provided with sufficient resources. The same situation could be happening in other WEC.</div></div>","PeriodicalId":72916,"journal":{"name":"Enfermedades infecciosas y microbiologia clinica (English ed.)","volume":"43 7","pages":"Pages 426-434"},"PeriodicalIF":0.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144227845","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}